PL3929190T3 - Związki i kompozycje do modulowania aktywności zmutowanych kinaz egfr - Google Patents
Związki i kompozycje do modulowania aktywności zmutowanych kinaz egfrInfo
- Publication number
- PL3929190T3 PL3929190T3 PL21171619.6T PL21171619T PL3929190T3 PL 3929190 T3 PL3929190 T3 PL 3929190T3 PL 21171619 T PL21171619 T PL 21171619T PL 3929190 T3 PL3929190 T3 PL 3929190T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- compounds
- kinase activities
- egfr mutant
- mutant kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quick-Acting Or Multi-Walled Pipe Joints (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063394P | 2014-10-13 | 2014-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3929190T3 true PL3929190T3 (pl) | 2025-06-09 |
Family
ID=55654993
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21171619.6T PL3929190T3 (pl) | 2014-10-13 | 2015-10-13 | Związki i kompozycje do modulowania aktywności zmutowanych kinaz egfr |
| PL19196713T PL3604294T3 (pl) | 2014-10-13 | 2015-10-13 | Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR |
| PL15850314T PL3207035T3 (pl) | 2014-10-13 | 2015-10-13 | Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19196713T PL3604294T3 (pl) | 2014-10-13 | 2015-10-13 | Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR |
| PL15850314T PL3207035T3 (pl) | 2014-10-13 | 2015-10-13 | Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9593098B2 (enExample) |
| EP (4) | EP3207035B1 (enExample) |
| JP (3) | JP6524221B2 (enExample) |
| KR (5) | KR102073854B1 (enExample) |
| CN (2) | CN111686110B (enExample) |
| AU (1) | AU2015331166B2 (enExample) |
| BR (1) | BR112017007769B1 (enExample) |
| CA (1) | CA2962914C (enExample) |
| CY (2) | CY1122737T1 (enExample) |
| DK (3) | DK3929190T3 (enExample) |
| ES (3) | ES2770058T3 (enExample) |
| FI (2) | FI3929190T3 (enExample) |
| FR (1) | FR25C1021I1 (enExample) |
| HR (3) | HRP20250213T1 (enExample) |
| HU (4) | HUE070874T2 (enExample) |
| LT (4) | LT3604294T (enExample) |
| MX (3) | MX2017003181A (enExample) |
| NL (1) | NL301329I2 (enExample) |
| NO (1) | NO2025025I1 (enExample) |
| NZ (1) | NZ730012A (enExample) |
| PH (1) | PH12017500488A1 (enExample) |
| PL (3) | PL3929190T3 (enExample) |
| PT (3) | PT3207035T (enExample) |
| RS (3) | RS61865B1 (enExample) |
| RU (1) | RU2727700C2 (enExample) |
| SG (1) | SG11201701960XA (enExample) |
| SI (3) | SI3604294T1 (enExample) |
| SM (3) | SMT202000059T1 (enExample) |
| TW (2) | TWI664173B (enExample) |
| WO (1) | WO2016060443A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073854B1 (ko) * | 2014-10-13 | 2020-02-05 | 주식회사유한양행 | Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| RU2751341C2 (ru) | 2016-05-26 | 2021-07-13 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Соединения-ингибиторы egfr |
| KR102030886B1 (ko) * | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| CN108707139B (zh) * | 2017-06-13 | 2021-04-06 | 北京鞍石生物科技有限责任公司 | 氨基嘧啶类化合物及其制备方法和应用 |
| CA3069408A1 (en) * | 2017-07-28 | 2019-01-31 | Yuhan Corporation | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same |
| BR112020001278A2 (pt) * | 2017-07-28 | 2020-07-21 | Yuhan Corporation | processo aprimorado para preparar derivados de aminopirimidina |
| EA038078B1 (ru) * | 2017-07-28 | 2021-07-02 | Юхан Корпорейшн | Промежуточные соединения, используемые для синтеза селективного ингибитора протеинкиназы, и способы их получения |
| JP6985764B2 (ja) * | 2017-08-30 | 2021-12-22 | 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. | アミノピリミジン系化合物、この化合物を含む組成物およびそれらの使用 |
| CN108047207A (zh) * | 2018-01-30 | 2018-05-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用 |
| CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| WO2020125391A1 (zh) * | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
| WO2020174370A2 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| KR102318875B1 (ko) * | 2019-03-19 | 2021-11-01 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| MA55508A (fr) | 2019-03-29 | 2022-02-09 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
| EP3968985A4 (en) * | 2019-05-14 | 2023-07-26 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TW202207940A (zh) | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| JP2023542296A (ja) | 2020-09-14 | 2023-10-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｆｇｆｒ阻害剤の併用療法 |
| TWI867047B (zh) * | 2020-09-18 | 2024-12-21 | 南韓商沃若諾伊公司 | 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物 |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| KR20220085735A (ko) * | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| WO2022234965A1 (ko) * | 2021-05-07 | 2022-11-10 | 주식회사 보로노이 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| EP4342895A4 (en) | 2021-05-17 | 2025-09-10 | Voronoi Inc | HETEROARYL DERIVATIVE COMPOUND AND ITS USE |
| EP4349835A4 (en) | 2021-06-01 | 2025-06-25 | Hangzhou Solipharma Co., Ltd. | Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| JP2025516171A (ja) | 2022-04-28 | 2025-05-27 | アストラゼネカ・アクチエボラーグ | 縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用 |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| EP4543920A1 (en) | 2022-06-27 | 2025-04-30 | Astrazeneca AB | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CA3261476A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
| CN116655600B (zh) * | 2023-05-23 | 2025-08-22 | 江南大学 | 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025017409A1 (en) | 2023-07-14 | 2025-01-23 | Janssen Biotech, Inc. | Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9815453A (pt) | 1997-03-11 | 2001-10-23 | Du Pont | Composto, composição herbicida e método para controle do crescimento de vegetação indesejada |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| EP1345926B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| AU2002363176B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) |
| EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| JP4428565B2 (ja) | 2004-10-05 | 2010-03-10 | 東京エレクトロン株式会社 | 処理液塗布装置 |
| RU2007114080A (ru) | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
| EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| US20070072894A1 (en) | 2005-03-24 | 2007-03-29 | Kempf J V | Synthesis of pyrroloquinoline quinone (PQQ) |
| JP5007029B2 (ja) | 2005-07-13 | 2012-08-22 | Ｎｔｎ株式会社 | グリース組成物および該グリース封入転がり軸受 |
| AU2006283935A1 (en) | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | Fused pyrazole as p38 MAP kinase inhibitors |
| JP2007117465A (ja) | 2005-10-28 | 2007-05-17 | Sharp Corp | 集塵器およびそれを備えた電気掃除機 |
| GB2450046B (en) | 2006-03-29 | 2011-03-09 | Kt Freetel Co Ltd | Digital device and method for providing additional service by using the same |
| CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| BRPI0709949A2 (pt) | 2006-04-12 | 2011-08-30 | Wyeth Corp | composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| CA3031835C (en) * | 2008-06-27 | 2021-09-07 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| MX2012005332A (es) | 2009-11-13 | 2012-10-15 | Oscotec Inc | Inhibidores de cinasa. |
| CA2827072C (en) | 2011-02-25 | 2019-01-08 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
| CN105198862B (zh) * | 2011-07-27 | 2018-01-23 | 阿斯利康(瑞典)有限公司 | 取代的n‑(4‑氟‑2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐 |
| JP6062962B2 (ja) * | 2012-01-20 | 2017-01-18 | ジェノスコ | 置換ピリミジン化合物およびｓｙｋ阻害剤としてのそれらの使用 |
| WO2014040555A1 (zh) * | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US10273224B2 (en) * | 2013-08-22 | 2019-04-30 | Jubilant Biosys Limited | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN111892579B (zh) * | 2014-06-12 | 2023-07-25 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
| SG11201610517PA (en) | 2014-06-19 | 2017-01-27 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
| KR102073854B1 (ko) | 2014-10-13 | 2020-02-05 | 주식회사유한양행 | Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
-
2015
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Active
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 SI SI201532056T patent/SI3929190T1/sl unknown
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en not_active Ceased
- 2015-10-13 PL PL21171619.6T patent/PL3929190T3/pl unknown
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 DK DK21171619.6T patent/DK3929190T3/da active
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 PT PT211716196T patent/PT3929190T/pt unknown
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 SM SM20200059T patent/SMT202000059T1/it unknown
- 2015-10-13 FI FIEP21171619.6T patent/FI3929190T3/fi active
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 HR HRP20250213TT patent/HRP20250213T1/hr unknown
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 SM SM20210266T patent/SMT202100266T1/it unknown
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active Active
- 2015-10-13 EP EP24166947.2A patent/EP4421069B1/en active Active
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 KR KR1020247013986A patent/KR20240074820A/ko active Pending
- 2015-10-13 HU HUE21171619A patent/HUE070874T2/hu unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190B1/en active Active
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 RS RS20250168A patent/RS66529B1/sr unknown
- 2015-10-13 SM SM20250069T patent/SMT202500069T1/it unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active Active
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active Active
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 ES ES21171619T patent/ES3009926T3/es active Active
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 US US14/881,930 patent/US9593098B2/en not_active Ceased
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 LT LTEP21171619.6T patent/LT3929190T/lt unknown
- 2015-10-13 MX MX2020002168A patent/MX385942B/es unknown
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
-
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
-
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
-
2020
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
-
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown
-
2022
- 2022-11-18 US US18/057,062 patent/USRE50528E1/en active Active
-
2025
- 2025-05-28 NL NL301329C patent/NL301329I2/nl unknown
- 2025-06-02 HU HUS2500023C patent/HUS2500023I1/hu unknown
- 2025-06-03 LT LTPA2025522C patent/LTPA2025522I1/lt unknown
- 2025-06-03 FR FR25C1021C patent/FR25C1021I1/fr active Active
- 2025-06-05 NO NO2025025C patent/NO2025025I1/no unknown
- 2025-06-06 FI FIC20250023C patent/FIC20250023I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500023I1 (hu) | Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására | |
| IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
| IL273058A (en) | Compositions and methods for modulation of PKK expression | |
| ZA201801600B (en) | Compounds and methods for modulating angiotensinogen expression | |
| SG11201802798WA (en) | Compounds, compositions, and methods for modulating cftr | |
| IL252554A0 (en) | A history of mutated 2-anilinopyrimidines as egfr modulators | |
| IL246879B (en) | Preparations of Epilimod and methods of using them | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| HUE037848T2 (hu) | Vegyes gyep | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| SG10202003691PA (en) | Composition for modulating irak1 | |
| GB201614961D0 (en) | Compounds and compositions for use | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |